Submissions for variant NM_000251.3(MSH2):c.2113del (p.Val705fs)

dbSNP: rs63749811

Total submissions: 10

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
International Society for Gastrointestinal Hereditary Tumours (InSiGHT)	RCV000030250	SCV000107421	pathogenic	Lynch syndrome	2013-09-05	reviewed by expert panel	research	Coding sequence variation introducing premature termination codon
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV001175339	SCV000052917	pathogenic	Hereditary nonpolyposis colon cancer	2019-07-15	criteria provided, single submitter	clinical testing	Variant summary: MSH2 c.2113delG (p.Val705TrpfsX5) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251476 control chromosomes. c.2113delG has been reported in the literature in multiple individuals affected with Lynch Syndrome (Moslein_1996, Lin_1999, Hegde_2005, Nilbert_2009, Coolbaugh-Murphy_2010). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Ambry Genetics	RCV000223638	SCV000278375	pathogenic	Hereditary cancer-predisposing syndrome	2022-01-26	criteria provided, single submitter	clinical testing	The c.2113delG pathogenic mutation, located in coding exon 13 of the MSH2 gene, results from a deletion of one nucleotide at nucleotide position 2113, causing a translational frameshift with a predicted alternate stop codon (p.V705Wfs*5). This mutation has been detected in multiple individuals with hereditary non-polyposis colorectal cancer (HNPCC)/Lynch syndrome; several with family histories meeting Amsterdam criteria (Jeon HM et al. Hum. Mutat., 1996;7:327-33; Moslein G et al. Hum Mol Genet, 1996 Sep;5:1245-52)(Lin X et al. Dig. Dis. Sci., 1999 Mar;44:553-9; Domingo E et al. J Med Genet, 2004 Sep;41:664-8; Nilbert M et al. Fam Cancer, 2009 Jun;8:75-83; Coolbaugh-Murphy MI et al. Hum Mutat, 2010 Mar;31:317-24; Cloyd JM et al. J Gastrointest Cancer, 2018 Mar;49:93-96). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Invitae	RCV000791368	SCV000548168	pathogenic	Hereditary nonpolyposis colorectal neoplasms	2024-01-27	criteria provided, single submitter	clinical testing	This sequence change creates a premature translational stop signal (p.Val705Trpfs*5) in the MSH2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Lynch syndrome and Lynch syndrome-related cancers (PMID: 8723682, 8872463, 18566915, 20052760). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 1760). For these reasons, this variant has been classified as Pathogenic.
GeneDx	RCV000482957	SCV000568634	pathogenic	not provided	2022-11-25	criteria provided, single submitter	clinical testing	Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Observed in individuals with a personal or family history consistent with pathogenic variants in this gene, and segregates with disease in many affected individuals (Jeon et al. 1996; Moslein et al., 1996; Lin et al., 1999; Domingo et al., 2004; Hegde et al., 2005; Nilbert et al., 2009; Coolbaugh-Murphy et al., 2010); Not observed at significant frequency in large population cohorts (gnomAD); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; This variant is associated with the following publications: (PMID: 20052760, 15342696, 29238914, 16237223, 10080150, 8872463, 18566915, 8723682, 30787465)
Quest Diagnostics Nichols Institute San Juan Capistrano	RCV000482957	SCV000601455	pathogenic	not provided	2022-11-04	criteria provided, single submitter	clinical testing	This frameshift variant alters the translational reading frame of the MSH2 mRNA and causes the premature termination of MSH2 protein synthesis. This variant has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). In the published literature, the variant has been reported in individuals with hereditary nonpolyposis colorectal cancer (HNPCC) (PMID: 8723682 (2996), 8872463 (1996), 10080150 (1999), 15342696 (2004), 16237223 (2005), 20052760 (2010)). It has also been reported in individuals with Lynch Syndrome (PMID: 18566915 (2009), 29238914 (2018)). Based on the available information, this variant is classified as pathogenic.
Color Diagnostics, LLC DBA Color Health	RCV000223638	SCV001347251	pathogenic	Hereditary cancer-predisposing syndrome	2022-10-18	criteria provided, single submitter	clinical testing	This variant deletes 1 nucleotide in exon 13 of the MSH2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in multiple individuals and families affected with Lynch syndrome (PMID: 8723682, 8872463, 10080150, 18566915, 20052760, 29238914). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of MSH2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
Sema4, Sema4	RCV000223638	SCV002534447	pathogenic	Hereditary cancer-predisposing syndrome	2020-11-02	criteria provided, single submitter	curation
Myriad Genetics, Inc.	RCV000001830	SCV004188027	pathogenic	Lynch syndrome 1	2023-08-07	criteria provided, single submitter	clinical testing	This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.
OMIM	RCV000001830	SCV000021986	pathogenic	Lynch syndrome 1	1996-01-01	no assertion criteria provided	literature only